Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Microvasc Res ; 89: 134-45, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23628292

ABSTRACT

OBJECTIVES: We investigated the effect of suppressing plasma angiotensin II (ANG II) levels on arteriolar relaxation in the hamster cheek pouch. METHODS: Arteriolar diameters were measured via television microscopy during short-term (3-6days) high salt (HS; 4% NaCl) diet and angiotensin converting enzyme (ACE) inhibition with captopril (100mg/kg/day). RESULTS: ACE inhibition and/or HS diet eliminated endothelium-dependent arteriolar dilation to acetylcholine, endothelium-independent dilation to the NO donor sodium nitroprusside, the prostacyclin analogs carbacyclin and iloprost, and the KATP channel opener cromakalim; and eliminated arteriolar constriction during KATP channel blockade with glibenclamide. Scavenging of superoxide radicals and low dose ANG II infusion (25ng/kg/min, subcutaneous) reduced oxidant stress and restored arteriolar dilation in arterioles of HS-fed hamsters. Vasoconstriction to topically-applied ANG II was unaffected by HS diet while arteriolar responses to elevation of superfusion solution PO2 were unaffected (5% O2, 10% O2) or reduced (21% O2) by HS diet. CONCLUSIONS: These findings indicate that sustained exposure to low levels of circulating ANG II leads to widespread dysfunction in endothelium-dependent and independent vascular relaxation mechanisms in cheek pouch arterioles by increasing vascular oxidant stress, but does not potentiate O2- or ANG II-induced constriction of arterioles in the distal microcirculation of normotensive hamsters.


Subject(s)
Angiotensin II/metabolism , Endothelium, Vascular/pathology , Oxidants/chemistry , Acetylcholine/chemistry , Animals , Arterioles/drug effects , Arterioles/metabolism , Blood Pressure , Captopril/chemistry , Cheek/blood supply , Cricetinae , Cromakalim/chemistry , Epoprostenol/analogs & derivatives , Epoprostenol/chemistry , Glyburide/chemistry , Iloprost/chemistry , Male , Mesocricetus , Microscopy , Microscopy, Video , Nitroprusside/chemistry , Oxygen/chemistry , Peptidyl-Dipeptidase A/metabolism , Superoxides/chemistry , Vascular Diseases/pathology
2.
Am J Physiol Heart Circ Physiol ; 297(4): H1296-303, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19684181

ABSTRACT

This study identified, on the integrative level, two components of the ANG II signaling pathway that lay downstream from the ANG II type 1 (AT(1)) receptor and are critically involved in maintaining vascular relaxation in cerebral resistance arteries. In these experiments, the relaxation of isolated middle cerebral arteries (MCA) in response to ACh (10(-9)-10(-5) M), iloprost (10(-16)-10(-11) g/ml), and reduced PO(2) was lost and the ratio of phospho-ERK/ERK1/2 was significantly reduced in aortas of male Sprague-Dawley rats fed a high-salt (HS; 4% NaCl) diet to suppress plasma ANG II levels. In salt-fed rats, relaxation of MCA in response to these vasodilator stimuli was restored by chronic (3 days) intravenous infusion of either ANG II (5 ngxkg(-1)xmin(-1)) or epidermal growth factor (EGF; 2 microg/h). The protective effect of ANG II infusion to restore vascular relaxation was eliminated by coinfusion of either the EGF receptor kinase inhibitor AG-1478 (20 microg/h), the ERK1/2 inhibitor PD-98059 (10 microg/h), or the protein synthesis inhibitor cycloheximide (5 microg/h). In rats fed a low-salt (0.4% NaCl) diet, MCA relaxation in response to ACh, reduced PO(2), and iloprost was eliminated by intravenous infusion of AG-1478, PD-98059, or cycloheximide. In ANG II-infused rats fed HS diet, and in rats fed LS diet, vasodilator responses to reduced PO(2) and iloprost were unaffected by the p38 MAP kinase inhibitor SB-203580 and the phosphatidylinositol 3-kinase inhibitor wortmannin. These findings indicate that maintenance of normal vascular relaxation mechanisms by ANG II in rat MCA requires activation of the EGF receptor kinase and ERK1/2.


Subject(s)
Angiotensin II/metabolism , Epidermal Growth Factor/metabolism , ErbB Receptors/metabolism , Hypertension/enzymology , Middle Cerebral Artery/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Vasodilation , Angiotensin II/administration & dosage , Animals , Blood Pressure , Disease Models, Animal , Dose-Response Relationship, Drug , Epidermal Growth Factor/administration & dosage , ErbB Receptors/antagonists & inhibitors , Hypertension/etiology , Hypertension/physiopathology , Infusions, Intravenous , Male , Middle Cerebral Artery/drug effects , Middle Cerebral Artery/physiopathology , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Protein Synthesis Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley , Receptor Cross-Talk , Receptor, Angiotensin, Type 1/metabolism , Signal Transduction , Sodium Chloride, Dietary , Vasodilation/drug effects , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...